US FDA approves CombinatoRx/Covidien's extended-release Exalgo for pain
03 March 2010
Asher Mullard
Please Login to read the full article.
03 March 2010
Asher Mullard
asher.mullard@informa.com
The US FDA has approved CombinatoRx/ Covidien's Exalgo (extended-release hydromorphone) for the management of moderate to severe pain in opioid-tolerant patients who need around-the-clock analgesia.
"Investor expectations were low given two extensions of the PDUFA date and the long-dated...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Janssen wins US FDA nod for chronic pain drug Nucynta ER
- BDSI CEO: Shared fentanyl REMS puts Onsolis on level playing field
- PharmacoFore secures $10M Series B to advance "next generation" abuse resistant opioids, plus propofol alternative
- US FDA accepts Vivus NDA resubmission for obesity drug
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
